Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical ...

Dr. Ma discussed key findings that have been shared so far this year on the topic of evolving treatment strategies for ...

Surgery is a mainstay treatment for head and neck squamous cell carcinoma (HNSCC). However, the clinical challenge is to ...

Non-Small Cell Lung Cancer Market grows as immunotherapy approvals by Merck & Bristol-Myers reshape global treatment pathways. Anurag Tiwari Orion Market Research Pvt Ltd +91 91798 28694 email us here ...

Cutaneous squamous cell carcinoma (cSCC) is also usually a localised skin cancer. In a small proportion of cases it can spread to other parts of the body, so the best treatment is to remove it using ...

A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed ...

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

Neoadjuvant immunotherapy in combination with chemotherapy in resectable locally advanced head and neck squamous cell carcinoma: A randomized, open label, phase II clinical trial.. If you have the ...

Ficerafusp alfa with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: Updated results from an expansion cohort of an open-label, multicenter, phase 1/1b ...

A patient shares his experience with a squamous cell carcinoma diagnosis, treatment and recovery.

The Food and Drug Administration has approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma.

An FDA approval was granted for cosibelimab-ipdl for the treatment of patients with locally advanced or metastatic cutaneous squamous cell carcinoma.